Licensed vaccine
TICOVAC
FDA-licensed vaccine · Pfizer Ireland Pharmaceuticals · STN 125740
Key facts
| Trade name | TICOVAC |
|---|---|
| Proper name | Tick-Borne Encephalitis Vaccine |
| Manufacturer | Pfizer Ireland Pharmaceuticals |
| Submission tracking number (STN) | 125740 |
| FDA product areas | Biologics |
| Recent FDA documents | Approval History, Letters, Reviews, and Related Documents - TICOVAC, Statistical Review - TICOVAC, August 13, 2021 Clinical Review Memo - TICOVAC, August 13, 2021 Summary Basis for Regulatory Action - TICOVAC, August 13, 2021 Approval Letter - TICOVAC, Package Insert - TICOVAC |
| FDA page updated | Sep 7, 2021 |
| FDA product page | fda.gov |
At a glance
- 1–9 FDA approval letters
- 1–9 Supporting documents
- 1–9 Product information documents
- Yes Document full text searchable in Orca1
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About FDA-licensed vaccines
The FDA's CBER licenses vaccines for use in the United States. Each product page links the approval letters, package inserts and supporting documents for that vaccine.
Source: U.S. Food and Drug Administration (FDA), Center for Biologics Evaluation and Research (CBER), Vaccines Licensed for Use in the United States · Source date: